[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:hras-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"HRAS Gene",8,7,[8,16,22,28,35,41,47,53],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07318324","Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:17:46.653867Z","2026-07-05T05:32:16.676290Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06096974","Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS",[12],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:28.566526Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT07252479","Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations",[12],"2026-08-26T02:16:01.910993Z","2026-06-16T05:54:07.937487Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT03190941","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients",[32],"Phase 1\u002FPhase 2","2026-08-26T02:18:06.247899Z","2026-05-05T02:43:28.129328Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05786924","Phase 1\u002F2 Trial of S241656 in Selected RAS\u002FMAPK Mutation- Positive Malignancies",[32],"2026-08-26T02:16:54.044282Z","2026-05-05T02:35:31.640479Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05111561","Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced\u002FMetastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer",[12],"2026-08-26T02:17:47.813245Z","2026-07-24T01:27:14.906567Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT04888936","Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies",[],"2026-08-26T02:17:59.904383Z","2026-05-13T02:55:06.274852Z",{"nct_id":54,"title":55,"phases":56,"status":58,"updated_at":59,"content_modified":60},"NCT05554328","Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial",[57],"Phase 2","ACTIVE_NOT_RECRUITING","2026-08-03T03:36:04.680662Z","2026-05-05T02:43:27.963217Z"]